Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Fourteen analysts cover CAH, with most assigning a "Buy" recommendation.
  • Average 12-month price target stands at USD 158.07 per MarketBeat data.
  • Multiple brokerages raised targets in recent months amid industry demand trends.

Shares of Cardinal Health, Inc. (NYSE: CAH) have received a consensus recommendation of “Moderate Buy” from fourteen research firms currently tracking the stock. Out of these, three analysts rate the stock as “Hold,” while eleven have issued “Buy” ratings.

The average 12-month target price across these brokerages is USD 158.07, suggesting a measured upside from recent market levels. Cardinal Health operates as a healthcare services and products provider across the United States, Canada, Europe, Asia, and other international markets. Its offerings span customized solutions for hospitals, pharmacies, healthcare systems, ambulatory surgery centers, laboratories, physician offices, and home-based patient care.

Several brokerages have recently updated their views on CAH. On June 12th, Evercore ISI reaffirmed its “Outperform” rating, increasing its price target from USD 175.00 to USD 180.00. Citigroup maintained a “Neutral” stance on June 13th but raised its target from USD 157.00 to USD 170.00. Earlier, on May 2nd, Robert W. Baird increased its target from USD 156.00 to USD 170.00, reiterating an “Outperform” rating.

Morgan Stanley adjusted its outlook on July 16th, lifting the target price from USD 181.00 to USD 190.00 and assigning an “Overweight” rating. UBS Group also revised its target on April 29th from USD 150.00 to USD 160.00 while maintaining a “Buy” rating. The range of price objectives reflects differing views on the company’s growth trajectory, profitability outlook, and positioning in the healthcare supply chain.

Cardinal Health’s performance is influenced by demand for medical products and services, shifts in healthcare spending, and operational efficiency in distribution and logistics. Analysts with higher price targets often cite the company’s diversified customer base, international footprint, and potential for incremental margin improvements. Conversely, those maintaining more neutral stances point to competitive pressures, regulatory factors, and macroeconomic headwinds that could temper near-term performance.